Sex hormones in postmenopausal women receiving low-dose hormone therapy: The effect of BMI

Obesity

Volumn 19, Issue 5, 2011, Pages 988-993

  Lambrinoudaki, Irene ^a   Armeni, Eleni ^a   Rizos, Demetrios ^a   Deligeoroglou, Eythimios ^a   Kofinakos, Panagiotis ^a   Kaparos, George ^a   Alexandrou, Andreas ^b   Creatsa, Maria ^a   Logothetis, Emmanuel ^a   Kouskouni, Evangelia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; FOLLITROPIN; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NORMAL HUMAN; OPEN STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION;

ADIPOSE TISSUE; ANDROGENS; ANDROSTENEDIONE; BODY MASS INDEX; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; GREECE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 79955476562     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.232     Document Type: Article

References (33)

1. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-2838. (Pubitemid 32269161)
2. Al-Azzawi F, Palacios S. Hormonal changes during menopause. Maturitas 2009;63:135-137.
3. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 2007;19:635-641.
4. Gavaler JS. Oral hormone replacement therapy: Factors that influence the estradiol concentrations achieved in a multiracial study population. J Clin Pharmacol 2002;42:137-144. (Pubitemid 34101345)
5. Yasui T, Uemura H, Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. J Med Invest 2003;50:136-145. (Pubitemid 38019760)
6. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008;93:131-138.
7. Lee JS, Yaffe K, Lui LY et al. Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol 2010;67:195-201.
8. Kol S, Homburg R. Change, change, change: Hormonal actions depend on changes in blood levels. Hum Reprod 2008;23:1004-1006. (Pubitemid 351757327)
9. Weghofer A, Gleicher N. Ovarian function: A theory of relativity. Hum Reprod 2009;24(No. I):17-19.
10. Waaseth M, Bakken K, Dumeaux V et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort-a cross-sectional analysis. BMC Womens Health 2008;8:1.
11. Tworoger SS, Missmer SA, Barbieri RL et al. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 2005;97:595-602. (Pubitemid 40723787)
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies with 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059.
13. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427. (Pubitemid 36999703)
14. Rinaldi S, Geay A, Déchaud H et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002;11:1065-1071. (Pubitemid 35192658)
15. Sites CK, L'Hommedieu GD, Toth MJ et al. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005;90:2701-2707. (Pubitemid 40686312)
16. Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res 1976;20:425-430.
17. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-230. (Pubitemid 37412561)
18. Maggio M, Lauretani F, Basaria S et al. Sex hormone-binding globulin levels across the adult lifespan in women-the role of body mass index and fasting insulin. J Endocrinol Invest 2008;31:597-601.
19. Conner P, Söderqvist G, Skoog L et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-165.
20. Yasui T, Uemura H, Umino Y et al. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women. Maturitas 2005;50:19-29. (Pubitemid 39601705)
21. Karim R, Mack WJ, Hodis HN, Roy S, Stanczyk FZ. Influence of age and obesity on serum estradiol, estrone, and sex hormone-binding globulin concentrations following oral estrogen administration in postmenopausal women. J Clin Endocrinol Metab 2009;94:4136-4143.
22. Armamento-Villareal RC, Napoli N, Klug T, Civitelli R. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. Bone 2004;35:682-688. (Pubitemid 39141869)
23. Ribas V, Nguyen MTA, Henstridge DC et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice. Am J Physiol Endocrinol Metab 2010;298:E304-E319.
24. Salpeter SR, Walsh JM, Ormiston TM et al. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-554. (Pubitemid 44184248)
25. Redon J. Hypertension in obesity. Nutr Metab Cardiovasc Dis 2001;11: 344-353. (Pubitemid 33687823)
26. Messerli FH, Christie B, DeCarvalho JG et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981;141:81-85. (Pubitemid 11100827)
27. Fowke JH, Matthews CE. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate 2010;70:120-125.
28. Banez LL, Hamilton RJ, Partin AW et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-2280. (Pubitemid 350146217)
29. Biglia N, Ambroggio S, Ponzone R et al. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. Maturitas 2003;45:283-291. (Pubitemid 36966741)
30. Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-559. (Pubitemid 32175672)
31. Onobrakpeya OA, Fall PM, Willard A et al. Effect of norethindrone acetate on hormone levels and markers of bone turnover in estrogen-treated postmenopausal women. Endocr Res 2001;27:473-480. (Pubitemid 34042475)
32. Christodoulakos G, Lambrinoudaki I, Panoulis C et al. Serum androgen levels and insulin resistance in postmenopausal women: Association with hormone therapy, tibolone and raloxifene. Maturitas 2005;50:321-330. (Pubitemid 40365037)
33. Schairer C, Hill D, Sturgeon SR et al. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1660-1665. (Pubitemid 40995076)